Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol.

Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. J Exp Clin Cancer Res (2011) 1.15

Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol (2014) 0.90

Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res (2014) 0.83

Dermatological adverse events with taxane chemotherapy. Eur J Dermatol (2016) 0.81

The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. BMC Cancer (2015) 0.79

Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel. Support Care Cancer (2016) 0.75

Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP (2008) 2.39

Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP (2009) 1.57

Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55

Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44

Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP (2009) 1.43

Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. JOP (2014) 1.39

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38

Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev (2008) 1.38

The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev (2008) 1.34

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30

Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol (2007) 1.29

Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29

Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28

Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs (2009) 1.19

Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18

Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs (2006) 1.17

S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs (2009) 1.14

Cancers of the appendix: review of the literatures. ISRN Oncol (2011) 1.07

Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev (2010) 1.06

Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 1.06

Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP (2007) 1.06

First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 1.05

Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs (2010) 1.04

Primary squamous cell carcinoma of the liver. J Gastrointestin Liver Dis (2009) 1.03

Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs (2009) 1.02

Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.02

Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer (2009) 1.02

Advancements in the management of pancreatic cancer: 2013. JOP (2013) 1.02

Capecitabine: an overview of the side effects and their management. Anticancer Drugs (2008) 1.00

Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00

Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00

Capecitabine and hand-foot syndrome. Expert Opin Drug Saf (2010) 0.99

Gastrointestinal stromal tumors of the pancreas. JOP (2010) 0.98

Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med (2010) 0.97

Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol (2010) 0.96

IGF system in cancer: from bench to clinic. Anticancer Drugs (2011) 0.96

Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96

Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol (2009) 0.95

The role of endobronchial ultrasound in lung cancer diagnosis and staging: a comprehensive review. Clin Lung Cancer (2012) 0.95

The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer (2008) 0.95

Supportive and palliative care of pancreatic cancer. JOP (2007) 0.95

Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP (2008) 0.94

Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP (2010) 0.94

Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP (2008) 0.93

Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP (2007) 0.93

Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives. Cancer Metastasis Rev (2010) 0.91

FOLFIRINOX: from the ACCORD study to 2014. JOP (2014) 0.91

Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. Rev Inst Med Trop Sao Paulo (2006) 0.90

Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res (2010) 0.89

Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89

Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer (2011) 0.89

Pulmonary toxicity associated with gemcitabine. JOP (2010) 0.89

Renal oncocytoma: a case report and short review of the literature. Eur J Intern Med (2008) 0.89

Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP (2007) 0.89

Hypersensitivity reactions to antineoplastic agents: an overview. Anticancer Drugs (2009) 0.88

First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.88

Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol (2010) 0.88

Role of vitamin d in the prevention of pancreatic cancer. J Nutr Metab (2011) 0.88

Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin Colorectal Cancer (2008) 0.87

Early detection of pancreatic cancer. JOP (2012) 0.87

Medullary carcinoma of the colon: a case series and review of the literature. In Vivo (2014) 0.87

Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs (2009) 0.87

Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP (2009) 0.87

The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res (2009) 0.86

Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.86

Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 0.86

The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. J Oncol (2011) 0.86

Histones and lung cancer: Are the histone deacetylases a promising therapeutic target? Cancer Chemother Pharmacol (2013) 0.86

Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP (2011) 0.86

Update on novel therapies for pancreatic neuroendocrine tumors. JOP (2012) 0.86

From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer. Patholog Res Int (2011) 0.86

Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP (2013) 0.86

Quality of life in patients with pancreatic cancer. JOP (2012) 0.86

Gemcitabine-induced pulmonary toxicity. Anticancer Res (2012) 0.86

Nutritional status of patients with locally advanced pancreatic cancer: a pilot study. Support Care Cancer (2010) 0.85

Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma. Gastroenterol Res Pract (2011) 0.85

Pancreatic neuroendocrine tumors: entering a new era. JOP (2012) 0.85

Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? JOP (2011) 0.85

Secondary tumors of the pancreas: a case series. Anticancer Res (2012) 0.85

Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP (2008) 0.85

Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. Lung Cancer (2009) 0.85

Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP (2009) 0.85

Management of borderline resectable pancreatic adenocarcinoma. JOP (2012) 0.84

Cutaneous metastasis in a patient with pancreatic cancer. JOP (2011) 0.84

Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev (2008) 0.84

Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol (2010) 0.84

Metastatic cervical carcinoma to the thyroid gland: a case report and review of the literature. Yale J Biol Med (2006) 0.84

Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 0.84

Biomarkers for early detection and screening in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP (2009) 0.84

Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.84

Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer (2010) 0.84

Advancements in the management of pancreatic cancer. JOP (2009) 0.83

Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. JOP (2013) 0.83

First-line treatment for advanced pancreatic cancer. JOP (2013) 0.83